Subscribe
Magazine
Videos
Advertise
About Us
Smart Water Summit
Wastewater Summit
Drinking Water
Smart Water
Asset Management
Water Utility Management
Water Reuse
Global Thought Leaders
Podcast
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
WaterWorld Market Index
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Gracell Biotechnologies Inc ADR
(NQ:
GRCL
)
N/A
UNCHANGED
Last Price
Updated: 4:00 PM EST, Feb 21, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Gracell Biotechnologies Inc ADR
< Previous
1
2
3
4
5
6
Next >
Gracell Biotechnologies Announces China NMPA Clearance for IND Application for Phase 1/2 Clinical Trial of FasTCAR-T GC012F for the Treatment of Refractory Systemic Lupus Erythematosus
December 21, 2023
From
Gracell Biotechnologies Inc.
Via
GlobeNewswire
12 Health Care Stocks Moving In Tuesday's After-Market Session
December 12, 2023
Via
Benzinga
Gracell Biotechnologies Presents Updated Clinical Data from FasTCAR-T GC012F Demonstrating Deep and Durable Responses in Newly Diagnosed Multiple Myeloma at ASH 2023
December 11, 2023
From
Gracell Biotechnologies Inc.
Via
GlobeNewswire
Week In Review: Tang Capital Offers $465 Million For LianBio Plus 80% Of Any Licenses/Divestments
December 02, 2023
LianBio received a $465 million buyout offer from Tang Capital Management. In addition, Tang also offered shareholders a contingent value right for 80% of net proceeds from any license or divestment of...
Via
Talk Markets
A Preview Of Gracell Biotechnologies's Earnings
November 10, 2023
Via
Benzinga
The Latest Analyst Ratings for Gracell Biotechnologies
October 19, 2023
Via
Benzinga
Why SenesTech Shares Are Trading Lower By Around 50%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
November 28, 2023
Shares of SenesTech, Inc. (NASDAQ: SNES) shares moved lower during Tuesday’s session after the company reported pricing of $5.0 million public offering.
Via
Benzinga
12 Health Care Stocks Moving In Tuesday's Intraday Session
November 28, 2023
Via
Benzinga
Gracell Biotechnologies Announces FDA Clearance of IND Application for Phase 1/2 Clinical Trial of FasTCAR-T GC012F for the Treatment of Refractory Systemic Lupus Erythematosus
November 27, 2023
From
Gracell Biotechnologies Inc.
Via
GlobeNewswire
4 Analysts Have This to Say About Gracell Biotechnologies
August 30, 2023
Via
Benzinga
Preview: Gracell Biotechnologies's Earnings
August 11, 2023
Via
Benzinga
Bitfarms And Other Big Stocks Moving Lower On Friday
November 24, 2023
U.S. stocks traded mixed, with the Dow Jones gaining around 90 points on Friday. Shares of Bitfarms Ltd. (NASDAQ: BITF) shares fell sharply during Friday’s session after the company announced a C$60...
Via
Benzinga
Topics
Stocks
Exposures
US Equities
Gracell Biotechnologies to Participate in Inaugural Cell Therapy for Autoimmune Disease Summit
November 16, 2023
From
Gracell Biotechnologies Inc.
Via
GlobeNewswire
Gracell Biotechnologies Reports Third Quarter 2023 Unaudited Financial Results and Provides Corporate Update
November 13, 2023
From
Gracell Biotechnologies Inc.
Via
GlobeNewswire
Gracell Biotechnologies Wins Overall Immunology Solution of the Year by BioTech Breakthrough Awards Program
November 08, 2023
From
Gracell Biotechnologies Inc.
Via
GlobeNewswire
Earnings Scheduled For November 13, 2023
November 13, 2023
Companies Reporting Before The Bell • Sohu.com (NASDAQ:SOHU) is expected to report earnings for its third quarter. • Dixie Gr (NASDAQ:DXYN) is estimated to report earnings for its third quarter.
Via
Benzinga
Gracell Biotechnologies to Present Updated Results from BCMA/CD19 Dual-Targeting FasTCAR-T GC012F in Newly Diagnosed Multiple Myeloma at the 65ᵗʰ American Society of Hematology Annual Meeting & Exposition
November 02, 2023
From
Gracell Biotechnologies Inc.
Via
GlobeNewswire
Gracell Biotechnologies to Participate in Four Upcoming Investor Conferences
November 01, 2023
From
Gracell Biotechnologies Inc.
Via
GlobeNewswire
Gracell Biotechnologies to Present Data Highlighting Preclinical Efficacy of SMART CART™ Against Solid Tumors at Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting
October 31, 2023
From
Gracell Biotechnologies Inc.
Via
GlobeNewswire
Gracell Biotechnologies to Report Third Quarter 2023 Financials on Monday, November 13, 2023
October 30, 2023
From
Gracell Biotechnologies Inc.
Via
GlobeNewswire
Benzinga's Top Ratings Upgrades, Downgrades For October 19, 2023
October 19, 2023
Via
Benzinga
Week In Review: Adlai Nortye Stages $97.5 Million US IPO On Nasdaq
September 30, 2023
While ANL's IPO dropped more than 25% on its first day, netting just under $60M, private placement made up the difference. Plus: Deals, financings, trials and approvals.
Via
Talk Markets
Topics
Initial Public Offering
Exposures
Securities Market
Gracell Biotechnologies Reports Updated Clinical Data for FasTCAR-T GC012F for High-Risk, Newly Diagnosed Multiple Myeloma, Demonstrating 100% Stringent Complete Response Rate
September 27, 2023
From
Gracell Biotechnologies Inc.
Via
GlobeNewswire
Gracell Biotechnologies Doses First Patient in Phase 1b/2 Clinical Trial in U.S. Evaluating GC012F for Treatment of Relapsed/Refractory Multiple Myeloma
September 26, 2023
From
Gracell Biotechnologies Inc.
Via
GlobeNewswire
Gracell Biotechnologies’ CEO Dr. William Cao Named to Prestigious PharmaVoice 100, Honoring Most Inspiring Life Science Leaders
September 19, 2023
From
Gracell Biotechnologies Inc.
Via
GlobeNewswire
Gracell Biotechnologies to Participate in Three Upcoming Investor Conferences
September 14, 2023
From
Gracell Biotechnologies Inc.
Via
GlobeNewswire
Gracell Biotechnologies to Participate in Two Upcoming Investor Conferences
August 24, 2023
From
Gracell Biotechnologies Inc.
Via
GlobeNewswire
Gracell Biotechnologies Reports Second Quarter 2023 Unaudited Financial Results and Provides Corporate Update
August 14, 2023
From
Gracell Biotechnologies Inc.
Via
GlobeNewswire
Week In Review: BeiGene And Bristol-Myers Squibb Close BeiGene-Celgene PD-1 Partnership
August 12, 2023
BeiGene and Bristol-Myers Squibb have formally completed the breakup of the BeiGene-Celgene partnership, returning 23.3 million ordinary BeiGene shares to BeiGene. Meanwhile, Gracell Biotechnologies...
Via
Talk Markets
12 Health Care Stocks Moving In Monday's After-Market Session
August 07, 2023
Via
Benzinga
< Previous
1
2
3
4
5
6
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.